Our data indicated that 1 μmol/L fluoxetine did potentiate glucose‐induced insulin secretion from islets obtained from the obese donor, suggesting that obese individuals taking this SSRI would benefit from its direct effects to enhance insulin secretion and the lack of effect of fluoxetine on basal insulin secretion at 2 mmol/L glucose suggests that it is unlikely to induce hypoglycaemia in the fasting state. Here, INS is linked to Hypoglycemia.